EUCTR2021-000648-23-DE
Active, not recruiting
Phase 1
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluatethe Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment - A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of ABBV-154
ConditionsSubjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentMedDRA version: 21.0Level: PTClassification code 10036099Term: Polymyalgia rheumaticaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment
- Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Enrollment
- 160
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Adults at least 50 years of age with a clinical diagnosis of PMR and fulfillment of the 2012 EULAR/ACR provisional classification criteria for PMR.
- •2\. Following a confirmed diagnosis of PMR, subject must have shown a clinical response to prednisone (or equivalent).
- •3\. Subject must have had at least 2 episodes of unequivocal PMR flare while attempting to taper prednisone, with the dose of prednisone (or equivalent) at the time of flare \= 5 mg/day, prior to Baseline; the most recent flare must have been within 24 weeks of Baseline. Unequivocal PMR flare is defined as clinical signs and symptoms of PMR (shoulder and/or hip girdle pain with inflammatory stiffness, neck pain with inflammatory stiffness, or new or worsened limited range of
- •motion of hips and/or shoulders) that resulted in an increase in glucocorticoid dose.
- •4\. Subject must be on a stable prednisone (or equivalent) dose of 5 to 15 mg/day for \= 2 weeks prior to Baseline. Subjects may be on up to 25 mg/day at the Screening Visit provided that the subject is able to taper to 15 mg/day or less, with a stable dose \= 2 weeks prior to Baseline.
- •5\. Subject must be willing to follow the protocol\-defined glucocorticoid tapering regimen.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 32
Exclusion Criteria
- •1\. Subject must have discontinued use of immunomodulators other than prednisone (or equivalent) and hydroxychloroquine prior to Baseline.
- •2\. Subject must not exhibit clinical signs and symptoms of PMR (shoulder and/or hip girdle pain with inflammatory stiffness, neck pain with inflammatory stiffness, or new or worsened limited range of motion of hips and/or shoulders) within 2 weeks of Baseline
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study of ASN100 in Ventilated SubjectsEUCTR2016-002146-23-HUArsanis, Inc.354
Active, not recruiting
Phase 1
The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE)Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Therapeutic area: Diseases [C] - Immune System Diseases [C20]CTIS2024-510872-18-00Merck Healthcare KGaA508
Completed
Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentPMRpolymyalgia rheumatica10003816NL-OMON54200AbbVie Deutschland GmbH & Co. KG15
Active, not recruiting
Not Applicable
Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR MutatioCystic FibrosisMedDRA version: 13.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2009-010261-23-Outside-EU/EEAVertex Pharmaceuticals Incorporated140
Active, not recruiting
Not Applicable
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 InhibitorRheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2012-003439-41-DKVertex Pharmaceuticals Incorporated40